Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

2,055

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

November 11, 2021

Study Completion Date

November 30, 2021

Conditions
Acute Coronary SyndromeMyocardial InfarctionMyocardial IschemiaUnstable Angina
Interventions
DRUG

Rivaroxaban 2.5 mg

One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

DRUG

Rivaroxaban 5 mg

One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

DRUG

Enoxaparin

Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

Trial Locations (24)

410004

Changsha Central Hospital, Changsha

410005

Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha

410006

The Forth Hospital of Changsha, Changsha

410007

The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha

410011

The Second Xiangya Hospital of Central South University, Changsha

410013

The First Hospital of Changsha, Changsha

The Third Xiangya Hospital of Central South University, Changsha

410015

The Third Hospital of Changsha, Changsha

411400

Xiangxiang People's Hospital, Xianxiang

411413

Xiangtan Central Hospital, Xiangtan

412007

Zhuzhou Central Hospital, Zhuzhou

413000

Yiyang Central Hospital, Yiyang

414000

The First People's Hospital of Yueyang, Yueyang

415003

The First People's Hospital of Changde City, Changde

416000

The First Affiliated Hospital of Jishou University, Jishou

417000

The First People's Hospital of Loudi, Loudi

418000

The First Affiliated Hospital of Hunan University of Medicine, Huaihua

The First People's Hospital of Huaihua, Huaihua

421001

The First Affiliated Hospital of University of South China, Hengyang

The Second Affiliated Hospital of University of South China, Hengyang

422000

The Central Hospital of Shaoyang, Shaoyang

423000

The First People's Hospital of Chenzhou, Chenzhou

425000

Yongzhou First People's Hospital, Yongzhou

430100

The Second People's Hospital of Hunan Province, Changsha

All Listed Sponsors
lead

Second Xiangya Hospital of Central South University

OTHER

NCT03363035 - Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter